What is BeOne Medicines?
BeOne Medicines is a global biotechnology company focused on developing next-generation cancer treatments through innovative research and cutting-edge therapies. The company is committed to making these treatments accessible to patients worldwide, emphasizing speed, equity, and affordability in delivering care. Guided by the principle that cancer knows no borders, BeOne Medicines operates with a global perspective, striving to expand the reach of life-saving therapies and improve outcomes for patients everywhere. Its strategic focus on innovative research positions it as a key player in the fight against cancer.
How much funding has BeOne Medicines raised?
BeOne Medicines has raised a total of $4.8B across 7 funding rounds:
Series A
$75M
Series B
$96.6M
Stock Offering
$158M
Stock Offering
$200M
Multiple Rounds
$4.2B
Series A (2014): $75M with participation from CITIC Capital Holdings and Hillhouse Capital Group
Series B (2015): $96.6M led by Rock Springs Capital, T. Rowe Price, and Hillhouse Capital Group
Stock Issuance/Offering (2016): $158M, investors not publicly disclosed
Stock Issuance/Offering (2016): $200M, investors not publicly disclosed
Share Placement (2020): $2.8B backed by Amgen
Stock Issuance/Offering (2020): $421M with participation from Amgen Inc.
Private Equity (2020): $1B led by Hillhouse Capital
Key Investors in BeOne Medicines
Hillhouse Capital Group
Hillhouse Capital is an Asia-focused global private investment firm founded in 2005, with offices in Hong Kong, Beijing, and Singapore. They are known for their strategic investments across various sectors.
Rock Springs Capital
Rock Springs Capital is a Texas-based real estate firm with a history of investing and providing brokerage services since 1993, focusing on the Texas Triangle market.
T. Rowe Price
Founded in 1937, T. Rowe Price Group is a global asset management firm providing services to individuals and institutional investors, managing equity and fixed income mutual funds.
What's next for BeOne Medicines?
The recent major strategic investment in BeOne Medicines signals a strong validation of its research pipeline and therapeutic approach. This capital infusion is expected to accelerate the company's development programs, potentially enabling faster clinical trials and broader market penetration. As a company operating with a global perspective, this financing will likely support international expansion efforts and enhance its capacity to deliver life-saving therapies to a wider patient population. The sustained backing from prominent investors indicates confidence in BeOne Medicines' long-term vision and its potential to significantly impact cancer care worldwide.
See full BeOne Medicines company page
